FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2226973956> ?p ?o ?g. }

• W2226973956 endingPage "102" @default.
• W2226973956 startingPage "96" @default.
• W2226973956 abstract "The CD30-specific antibody–drug conjugate, brentuximab vedotin, is approved for the treatment of relapsed, refractory Hodgkin lymphomas and systemic anaplastic large T-cell lymphomas. Multiple ongoing clinical trials are investigating brentuximab vedotin efficacy in other CD30-positive hematologic malignancies. Because CD30 expression varies among different types of lymphoma and can also change during the course of treatment, companion diagnostic imaging of CD30 could be a valuable tool in optimizing patient-specific brentuximab vedotin treatment regimens. <b>Methods:</b> The mouse antihuman CD30 antibody AC-10 was radiolabeled with the positron-emitting radionuclide ⁸⁹Zr. The stability and specificity of ⁸⁹Zr-desferrioxamine (DFO)-labeled CD30-specific AC-10 antibody (⁸⁹Zr-DFO-AC-10) was evaluated in vitro. The pharmacokinetics of ⁸⁹Zr-DFO-AC-10 was studied in BALB/c nude mice bearing subcutaneous human Karpas 299 tumors (CD30-positive model) or A-431 tumors (CD30-negative model) using PET/CT imaging, biodistribution studies, and autoradiography. <b>Results:</b> AC-10 was conjugated with a DFO B chelator and radiolabeled with ⁸⁹Zr to give formulated ⁸⁹Zr-DFO-AC-10 with a radiochemical yield of 80%, radiochemical purity greater than 99%, and specific activity of 111–148 MBq/mg. ⁸⁹Zr-DFO-AC-10 was stable in mouse and human sera and preserved the immunoreactivity toward CD30. Biodistribution data showed the highest tissue accumulation of ⁸⁹Zr-DFO-AC-10 in CD30-positive tumors, with 37.9% ± 8.2% injected activity per gram of tissue at 72 h after injection, whereas uptake in CD30-negative tumors was 11.0% ± 0.4%. The specificity of ⁸⁹Zr-DFO-AC-10 binding to CD30 in vivo was confirmed by blocking studies. Time–activity curves showed that between 24 and 144 h after injection, tumor-to-muscle ratios increased from 18.9 to 51.8 in the CD30-positive model and from 4.8 to 8.7 in the CD30-negative model. Tumor-to-blood ratios also increased, from 3.2 to 13.6 and from 1 to 2 in the CD30-positive and -negative models, respectively. <b>Conclusion:</b> Our results demonstrate that for measuring CD30 expression, ⁸⁹Zr-DFO-AC-10 is a sensitive PET agent with high tumor–to–normal-tissue contrast. ⁸⁹Zr-DFO-AC-10 is a promising CD30-imaging radiotracer for clinical translation in patients with various lymphomas and other diseases." @default.
• W2226973956 created "2016-06-24" @default.
• W2226973956 creator A5013094846 @default.
• W2226973956 creator A5014626023 @default.
• W2226973956 creator A5024828770 @default.
• W2226973956 creator A5039176724 @default.
• W2226973956 creator A5055692967 @default.
• W2226973956 creator A5061689242 @default.
• W2226973956 creator A5076266268 @default.
• W2226973956 creator A5076884072 @default.
• W2226973956 date "2015-10-29" @default.
• W2226973956 modified "2023-10-16" @default.
• W2226973956 title "Immuno-PET Imaging of CD30-Positive Lymphoma Using ⁸⁹Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody" @default.
• W2226973956 cites W1987866733 @default.
• W2226973956 cites W2009347818 @default.
• W2226973956 cites W2021330461 @default.
• W2226973956 cites W2027324105 @default.
• W2226973956 cites W2037994583 @default.
• W2226973956 cites W2057600943 @default.
• W2226973956 cites W2060466778 @default.
• W2226973956 cites W2062486240 @default.
• W2226973956 cites W2062627275 @default.
• W2226973956 cites W2063423717 @default.
• W2226973956 cites W2067826728 @default.
• W2226973956 cites W2069422722 @default.
• W2226973956 cites W2070804960 @default.
• W2226973956 cites W2073276394 @default.
• W2226973956 cites W2074829227 @default.
• W2226973956 cites W2076831034 @default.
• W2226973956 cites W2078151758 @default.
• W2226973956 cites W2104527259 @default.
• W2226973956 cites W2104828126 @default.
• W2226973956 cites W2106974977 @default.
• W2226973956 cites W2115269770 @default.
• W2226973956 cites W2121828824 @default.
• W2226973956 cites W2122767481 @default.
• W2226973956 cites W2137277859 @default.
• W2226973956 cites W2139891818 @default.
• W2226973956 cites W2143145234 @default.
• W2226973956 cites W2150228337 @default.
• W2226973956 cites W2155256323 @default.
• W2226973956 cites W4230042643 @default.
• W2226973956 doi "https://doi.org/10.2967/jnumed.115.162735" @default.
• W2226973956 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26514172" @default.
• W2226973956 hasPublicationYear "2015" @default.
• W2226973956 type Work @default.
• W2226973956 sameAs 2226973956 @default.
• W2226973956 citedByCount "31" @default.
• W2226973956 countsByYear W22269739562016 @default.
• W2226973956 countsByYear W22269739562017 @default.
• W2226973956 countsByYear W22269739562018 @default.
• W2226973956 countsByYear W22269739562019 @default.
• W2226973956 countsByYear W22269739562020 @default.
• W2226973956 countsByYear W22269739562021 @default.
• W2226973956 countsByYear W22269739562022 @default.
• W2226973956 countsByYear W22269739562023 @default.
• W2226973956 crossrefType "journal-article" @default.
• W2226973956 hasAuthorship W2226973956A5013094846 @default.
• W2226973956 hasAuthorship W2226973956A5014626023 @default.
• W2226973956 hasAuthorship W2226973956A5024828770 @default.
• W2226973956 hasAuthorship W2226973956A5039176724 @default.
• W2226973956 hasAuthorship W2226973956A5055692967 @default.
• W2226973956 hasAuthorship W2226973956A5061689242 @default.
• W2226973956 hasAuthorship W2226973956A5076266268 @default.
• W2226973956 hasAuthorship W2226973956A5076884072 @default.
• W2226973956 hasBestOaLocation W22269739561 @default.
• W2226973956 hasConcept C142724271 @default.
• W2226973956 hasConcept C159654299 @default.
• W2226973956 hasConcept C177322064 @default.
• W2226973956 hasConcept C185592680 @default.
• W2226973956 hasConcept C202751555 @default.
• W2226973956 hasConcept C203014093 @default.
• W2226973956 hasConcept C2777325958 @default.
• W2226973956 hasConcept C2777807558 @default.
• W2226973956 hasConcept C2778191690 @default.
• W2226973956 hasConcept C2779338263 @default.
• W2226973956 hasConcept C2989005 @default.
• W2226973956 hasConcept C542903549 @default.
• W2226973956 hasConcept C55493867 @default.
• W2226973956 hasConcept C70905583 @default.
• W2226973956 hasConcept C71924100 @default.
• W2226973956 hasConceptScore W2226973956C142724271 @default.
• W2226973956 hasConceptScore W2226973956C159654299 @default.
• W2226973956 hasConceptScore W2226973956C177322064 @default.
• W2226973956 hasConceptScore W2226973956C185592680 @default.
• W2226973956 hasConceptScore W2226973956C202751555 @default.
• W2226973956 hasConceptScore W2226973956C203014093 @default.
• W2226973956 hasConceptScore W2226973956C2777325958 @default.
• W2226973956 hasConceptScore W2226973956C2777807558 @default.
• W2226973956 hasConceptScore W2226973956C2778191690 @default.
• W2226973956 hasConceptScore W2226973956C2779338263 @default.
• W2226973956 hasConceptScore W2226973956C2989005 @default.
• W2226973956 hasConceptScore W2226973956C542903549 @default.
• W2226973956 hasConceptScore W2226973956C55493867 @default.
• W2226973956 hasConceptScore W2226973956C70905583 @default.
• W2226973956 hasConceptScore W2226973956C71924100 @default.
• W2226973956 hasIssue "1" @default.
• W2226973956 hasLocation W22269739561 @default.

• next